DBV Technologies SA (FRA:DBV)
€ 0.737 0.087 (13.38%) Market Cap: 71.09 Mil Enterprise Value: 34.75 Mil PE Ratio: 0 PB Ratio: 1.32 GF Score: 36/100

Dbv Technologies SA at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 05:00PM GMT
Release Date Price: €3.49 (+3.99%)
Rajan Sharma
Goldman Sachs Group, Inc., Research Division - Research Analyst

Okay. Good morning, everyone. My name is Rajan Sharma. I'm the European biotech analyst here at Goldman Sachs. Pleased to have with us this morning, DBV and CEO, Daniel Tassé. Daniel, thank you for joining us and making the trip over.

Daniel TassÃ;DBV Technologies S.A.;CEO;Director

©,-&

Thanks for having me.

Rajan Sharma
Goldman Sachs Group, Inc., Research Division - Research Analyst

I mean, could you just kind of make a few introductory high-level comments and then we can dive into the Q&A.

Daniel TassÃ;DBV Technologies S.A.;CEO;Director

©,-&

Happy to. So DBV Technologies is a company that is specialized in immunology, specifically food allergy in children. The company was found about 15 years ago on observation made by our scientific founders that the human skin is actually very powerful and logical organ,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot